final os analysis from arches
Published 2 years ago • 53 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:35
arches: os by high or low disease volume and progression to mhspc or de novo mhspc
-
1:37
arches: os in mhspc who recieved prior adt and reached low psa further treated with enzalutamide
-
6:00
arches trial
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
1:57
monarcher: final os results of abemaciclib in hr , her breast cancer
-
2:37
arches trial: enzalutamide plus adt for mhspc
-
9:32
5 reasons not to do hyperbaric oxygen therapy
-
1:51:10
dr. virgiliu stroescu despre un stil de viață sănătos
-
6:05
esmo 2024: upper gi cancer update
-
6:05
enzamet trial
-
2:04
update on overall survival in arches trial
-
2:18
arches: enzalutamide plus adt in mhspc subgroups
-
10:02
why the improve & other trials comparing evar & open repair for ruptured aaa are misleading
-
44:49
'treatment landscape for metastatic hormone-sensitive prostate cancer' - dr laeeq malik grand rounds
-
3:57
update on arches trial: implications for prostate cancer treatment
-
19:44
emerging biomarkers and novel therapies for esophageal cancer
-
13:33
poly-metastatic hormone-sensitive disease
-
10:38
residual type a with arch dissection and descending aneurysm: total endo with a branched arch device
-
36:32
congenital variants and anomalies of the aorta dr. franklin ordoñez rivas
-
0:38
novel combined adcs in metastatic urothelial carcinoma: insights from esmo 2023
-
3:18
arches: radiographic progression in the absence of psa progression in patients with mhspc
-
1:03
dr. zhang on the arches trial in prostate cancer